Literature DB >> 14521606

Redistribution of glycoprotein Ib within platelets in response to protease-activated receptors 1 and 4: roles of cytoskeleton and calcium.

Y Han1, A Nurden, R Combrié, J-M Pasquet.   

Abstract

Thrombin activates human platelets by hydrolyzing the protease-activated receptors PAR-1 and PAR-4, exposing new N-terminal sequences which act as tethered ligands, and binding to glycoprotein (GP) Ib, whose surface accessibility transiently decreases when platelets are stimulated by the enzyme. In an attempt to better understand this latter process, we used the peptides SFLLRNPNDKYEPF (PAR-1-AP or TRAP) and AYPGKF (PAR-4-AP) to study whether hydrolysis of both PAR receptors leads to GPIb redistribution. Both peptides induced surface clearance of GPIb with a maximum at 2 min and 5 min for PAR-1-AP and PAR-4-AP, respectively, followed by a slow return to the surface with levels normalizing between 30 and 60 min. Translocation was associated with the formation of clusters of GPIb as revealed by fluorescence microscopy. This transient redistribution of GPIb was blocked by cytochalasin D and in large part by the membrane permeable Ca2+ chelator, BAPTA. The inhibitor of phosphatidylinositol 3-kinase and myosin light chain kinase, wortmannin, did not significantly modify internalization of GPIb, although its return to the surface was delayed for PAR-1-AP. PAR receptor-mediated association of GPIb to the insoluble cytoskeleton was blocked by cytochalasin D, while BAPTA alone increased and stabilized the presence of GPIb. Globally, immunoprecipitation experiments and analysis of the cytoskeleton confirmed that GPIb translocation is powered by a contractile mechanism involving Ca2+ mobilization, actin polymerization, and myosin incorporation into the cytoskeleton and that both PAR-1 and PAR-4 can activate this process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521606     DOI: 10.1046/j.1538-7836.2003.00436.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  3 in total

1.  Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.

Authors:  B Psaila; J B Bussel; A L Frelinger; B Babula; M D Linden; Y Li; M R Barnard; C Tate; E J Feldman; A D Michelson
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

2.  In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.

Authors:  Bethan Psaila; James B Bussel; Matthew D Linden; Bracken Babula; Youfu Li; Marc R Barnard; Chinara Tate; Kanika Mathur; Andrew L Frelinger; Alan D Michelson
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

3.  Activation-induced changes in platelet surface receptor expression and the contribution of the large-platelet subpopulation to activation.

Authors:  Masaaki Moroi; Richard W Farndale; Stephanie M Jung
Journal:  Res Pract Thromb Haemost       Date:  2020-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.